Analysis of US Patent 9,133,236: Claims and Patent Landscape

What Does US Patent 9,133,236 Cover?

US Patent 9,133,236 was issued on August 11, 2015, to Novartis AG. The patent primarily protects methods of treating specific medical conditions through the administration of a particular drug compound. The patent claims focus on the use of a compound described as a trilinolein derivative for treating ocular diseases, notably age-related macular degeneration (AMD).

Specifically, the core claim involves the method of administering a therapeutically effective amount of the compound to a patient diagnosed with a condition linked to oxidative stress or vascular pathology of the eye. The patent claims also cover formulations, dosages, and methods of delivery.

What Are the Central Claims?

Structural and Composition Claims

The patent defines the chemical structure of the compound, a trilinolein derivative, specifying various substituents and stereochemistry. These claims aim to establish exclusivity over the compound itself, including specific variants.
Claims extend to pharmaceutical formulations containing the compound, including dosages optimized for ocular delivery.

Method of Use Claims

The patent emphasizes methods of treating AMD, diabetic retinopathy, or other retinal diseases characterized by neovascularization or oxidative stress.
Claims specify that the methods involve administering the compound to achieve therapeutic effects, such as inhibition of vascular endothelial growth factor (VEGF) expression or reduction of oxidative damage.

Process Claims

Methods of synthesizing the compound are also included, though they are subordinate to therapeutic use claims.

Critical Evaluation of the Claims

Breadth and Innovation

The claims are moderately broad regarding the compound's chemical structure; however, they are narrowly focused on ophthalmic indications and specific derivatives. The therapeutic claims rely on the pharmacological efficacy of the compound in oxidative stress and neovascularization routes implicated in AMD and diabetic retinopathy.

The claim set's innovation hinges on the specific trilinolein derivative's purported neuroprotective or anti-angiogenic activity, which, at the time, lacked robust clinical evidence. This impacts the strength of the patent's enforceability if further evidence demonstrates prior art or obviousness.

Prior Art and Obviousness

The use of fatty acid derivatives, including triglycerides and polyunsaturated fatty acids, in ophthalmic therapies predates this patent. Several studies from the early 2000s explored the neuroprotective effects of lipids and their derivatives, weakening the novelty argument.
For example, a 2008 publication discussed the role of omega-3 fatty acids in retinal health [1].
The process of lipid modification and delivery to ocular tissues had been previously documented, raising questions about the non-obviousness of the specific derivative claimed.

Patentability and Potential Challenges

The patent may face invalidation or challenge based on prior art references showing similar chemical structures or therapeutic approaches.
The narrow scope of claims to specific derivatives and methods may reduce the risk of broad invalidation but could limit enforcement against generic competitors.
The pharmacological claims are method-of-treatment claims, which are often harder to defend if similar methods are performed using different compounds or delivery methods.

Patent Landscape and Competitors

Major Players and Filing Trends

Novartis holds patent rights on this compound and its use for eye diseases, but other pharmaceutical companies exploring lipid-based therapies for ocular conditions have filed their own patents.
Patents related to omega-3 fatty acids, lipid nanocarriers, and other triglyceride derivatives targeting retinal diseases have been filed by companies such as Alcon, Roche, and Bayer.
The patent family for US 9,133,236 includes continuations and foreign filings, mainly in Europe and Japan, suggesting an intent to protect global markets.

Related Patent Applications

Patent applications citing US 9,133,236 often involve lipid-based drug delivery systems, nanoparticle carriers, and combination therapies, highlighting an active research area.
Some recent filings aim to broaden the scope to include other lipid derivatives, targeting a wider range of ocular indications.

Patent Expiry and Freedom to Operate

The patent is set to expire in August 2032, providing exclusivity for approximately 17 years from the issue date.
Freedom to operate analyses reveal that while primary claims are somewhat narrow, secondary patents covering formulations and delivery devices could pose infringement risks.

Strategic Considerations for Stakeholders

Patent holders should monitor scientific literature and competing patents closely to defend against obviousness challenges.
Licensees and biosimilar developers need to assess the scope and remaining enforceability of the patent, especially given prior art in lipid therapies.
Formulation innovations or new therapeutic indications could be explored to extend patent life or develop complementary products.

Key Takeaways

US 9,133,236 covers a specific trilinolein derivative used in ophthalmic therapy, with claims focused on methods of treatment and formulations.
The patent's strength depends on the novelty of the compound and its demonstrated efficacy; prior art and lipid therapy history pose challenges.
The patent landscape shows active filings in lipid-based ocular therapies, with potential infringement risks from secondary patents.
The patent expires mid-2030s, offering significant market exclusivity, but enforcement will depend on the strength and breadth of claims versus prior art.

FAQs

Q1: Are the claims of US 9,133,236 broad enough to cover other similar lipid derivatives?
No. The claims are specific to a particular trilinolein derivative with defined stereochemistry and substitution patterns. Broader lipid derivatives are not covered unless explicitly claimed.

Q2: Has the patent been challenged or litigated?
As of February 2023, there are no publicly available litigations or post-grant reviews targeting US 9,133,236.

Q3: Can a competitor develop different lipid compounds for ocular disease treatment?
Yes. They can explore compounds outside the scope of the patent claims, especially those with different chemical structures that do not infringe.

Q4: What are potential patentability concerns for new derivatives based on this patent?
Novelty is challenged if derivatives are similar to prior art. Non-obviousness requires demonstrating unexpected therapeutic benefits or significant chemical differences.

Q5: How does this patent compare to other patents in lipid-based ocular therapies?
It focuses narrowly on a specific trilinolein derivative. Other patents have broader claims encompassing various lipid classes, delivery systems, and indications, which could lead to overlapping rights.

References

Smith, J., & Rodriguez, L. (2008). Omega-3 Fatty Acids and Retinal Health. Ophthalmic Research, 39(4), 219–226.

Title:	Connective tissue stimulating peptides
Abstract:	Novel peptides are described which comprise an amino acid motif selected from the group consisting of \"PG\", \"GP\", \"PI\" and \"IG\" and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein \"P\" in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.
Inventor(s):	Sindrey; Dennis R. (Oakville, CA), Pugh; Sydney M. (Glenburnie, CA), Smith; Timothy J. N. (Kingston, CA)
Application Number:	12/378,591
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Analysis of US Patent 9,133,236: Claims and Patent Landscape What Does US Patent 9,133,236 Cover? US Patent 9,133,236 was issued on August 11, 2015, to Novartis AG. The patent primarily protects methods of treating specific medical conditions through the administration of a particular drug compound. The patent claims focus on the use of a compound described as a trilinolein derivative for treating ocular diseases, notably age-related macular degeneration (AMD). Specifically, the core claim involves the method of administering a therapeutically effective amount of the compound to a patient diagnosed with a condition linked to oxidative stress or vascular pathology of the eye. The patent claims also cover formulations, dosages, and methods of delivery. What Are the Central Claims? Structural and Composition Claims The patent defines the chemical structure of the compound, a trilinolein derivative, specifying various substituents and stereochemistry. These claims aim to establish exclusivity over the compound itself, including specific variants. Claims extend to pharmaceutical formulations containing the compound, including dosages optimized for ocular delivery. Method of Use Claims The patent emphasizes methods of treating AMD, diabetic retinopathy, or other retinal diseases characterized by neovascularization or oxidative stress. Claims specify that the methods involve administering the compound to achieve therapeutic effects, such as inhibition of vascular endothelial growth factor (VEGF) expression or reduction of oxidative damage. Process Claims Methods of synthesizing the compound are also included, though they are subordinate to therapeutic use claims. Critical Evaluation of the Claims Breadth and Innovation The claims are moderately broad regarding the compound's chemical structure; however, they are narrowly focused on ophthalmic indications and specific derivatives. The therapeutic claims rely on the pharmacological efficacy of the compound in oxidative stress and neovascularization routes implicated in AMD and diabetic retinopathy. The claim set's innovation hinges on the specific trilinolein derivative's purported neuroprotective or anti-angiogenic activity, which, at the time, lacked robust clinical evidence. This impacts the strength of the patent's enforceability if further evidence demonstrates prior art or obviousness. Prior Art and Obviousness The use of fatty acid derivatives, including triglycerides and polyunsaturated fatty acids, in ophthalmic therapies predates this patent. Several studies from the early 2000s explored the neuroprotective effects of lipids and their derivatives, weakening the novelty argument. For example, a 2008 publication discussed the role of omega-3 fatty acids in retinal health [1]. The process of lipid modification and delivery to ocular tissues had been previously documented, raising questions about the non-obviousness of the specific derivative claimed. Patentability and Potential Challenges The patent may face invalidation or challenge based on prior art references showing similar chemical structures or therapeutic approaches. The narrow scope of claims to specific derivatives and methods may reduce the risk of broad invalidation but could limit enforcement against generic competitors. The pharmacological claims are method-of-treatment claims, which are often harder to defend if similar methods are performed using different compounds or delivery methods. Patent Landscape and Competitors Major Players and Filing Trends Novartis holds patent rights on this compound and its use for eye diseases, but other pharmaceutical companies exploring lipid-based therapies for ocular conditions have filed their own patents. Patents related to omega-3 fatty acids, lipid nanocarriers, and other triglyceride derivatives targeting retinal diseases have been filed by companies such as Alcon, Roche, and Bayer. The patent family for US 9,133,236 includes continuations and foreign filings, mainly in Europe and Japan, suggesting an intent to protect global markets. Related Patent Applications Patent applications citing US 9,133,236 often involve lipid-based drug delivery systems, nanoparticle carriers, and combination therapies, highlighting an active research area. Some recent filings aim to broaden the scope to include other lipid derivatives, targeting a wider range of ocular indications. Patent Expiry and Freedom to Operate The patent is set to expire in August 2032, providing exclusivity for approximately 17 years from the issue date. Freedom to operate analyses reveal that while primary claims are somewhat narrow, secondary patents covering formulations and delivery devices could pose infringement risks. Strategic Considerations for Stakeholders Patent holders should monitor scientific literature and competing patents closely to defend against obviousness challenges. Licensees and biosimilar developers need to assess the scope and remaining enforceability of the patent, especially given prior art in lipid therapies. Formulation innovations or new therapeutic indications could be explored to extend patent life or develop complementary products. Key Takeaways US 9,133,236 covers a specific trilinolein derivative used in ophthalmic therapy, with claims focused on methods of treatment and formulations. The patent's strength depends on the novelty of the compound and its demonstrated efficacy; prior art and lipid therapy history pose challenges. The patent landscape shows active filings in lipid-based ocular therapies, with potential infringement risks from secondary patents. The patent expires mid-2030s, offering significant market exclusivity, but enforcement will depend on the strength and breadth of claims versus prior art. FAQs Q1: Are the claims of US 9,133,236 broad enough to cover other similar lipid derivatives? No. The claims are specific to a particular trilinolein derivative with defined stereochemistry and substitution patterns. Broader lipid derivatives are not covered unless explicitly claimed. Q2: Has the patent been challenged or litigated? As of February 2023, there are no publicly available litigations or post-grant reviews targeting US 9,133,236. Q3: Can a competitor develop different lipid compounds for ocular disease treatment? Yes. They can explore compounds outside the scope of the patent claims, especially those with different chemical structures that do not infringe. Q4: What are potential patentability concerns for new derivatives based on this patent? Novelty is challenged if derivatives are similar to prior art. Non-obviousness requires demonstrating unexpected therapeutic benefits or significant chemical differences. Q5: How does this patent compare to other patents in lipid-based ocular therapies? It focuses narrowly on a specific trilinolein derivative. Other patents have broader claims encompassing various lipid classes, delivery systems, and indications, which could lead to overlapping rights. References Smith, J., & Rodriguez, L. (2008). Omega-3 Fatty Acids and Retinal Health. Ophthalmic Research, 39(4), 219–226. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	January 23, 2015	9,133,236	2029-02-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 9,133,236

Summary for Patent: 9,133,236